Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Jubilant Pharmova Ltd
Operating Income
Jubilant Pharmova Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
|
Operating Income
₹7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
6%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹67.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹58.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹122.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
4%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹28.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Operating Income
₹21.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jubilant Pharmova Ltd
Glance View
Once rooted as a modest family business, Jubilant Pharmova Ltd. has evolved into a global powerhouse in the pharmaceutical and life sciences industry. Founded by the visionary Bhartia family, the company has sprawled across continents, transforming healthcare landscapes with its robust product portfolio. Jubilant Pharmova's journey is one painted with strategic diversification, cleverly balancing risk and driving sustainable growth. At its core, the company operates through three primary segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Drug Discovery. Each arm serves as a critical piece in the company's strategic mosaic, enhancing its resilience amid the ever-fluctuating pharmaceutical market dynamics. Underpinning Jubilant Pharmova's business model is its Pharmaceuticals segment, which churns a significant portion of its revenue. The company manufactures and sells an array of pharmaceutical products, including generics and specialty pharmaceuticals, which cater to multiple therapeutic areas. Further driving its financial engine is the Contract Research and Development Service segment, which offers outsourced R&D solutions to a host of pharmaceutical majors—a sector that has witnessed burgeoning demand alongside escalating R&D costs globally. On the innovation frontier, the Proprietary Drug Discovery segment embarks on uncharted territories, seeking novel drugs and solutions, paving the path for the future. Such a diversified approach not only positions Jubilant Pharmova as a formidable entity in the pharmaceutical domain but also provides a cushion against industry-specific headwinds, reinforcing its long-term sustainability.
See Also
What is Jubilant Pharmova Ltd's Operating Income?
Operating Income
7.3B
INR
Based on the financial report for Dec 31, 2024, Jubilant Pharmova Ltd's Operating Income amounts to 7.3B INR.
What is Jubilant Pharmova Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
6%
Over the last year, the Operating Income growth was 145%. The average annual Operating Income growth rates for Jubilant Pharmova Ltd have been -7% over the past three years , -9% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet